Trial Profile
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Anagrelide
- Indications Essential thrombocythaemia
- Focus Registrational; Therapeutic Use
- Acronyms RESET-272
- Sponsors Incyte Corporation
- 12 May 2021 Status changed discontinued.
- 09 Nov 2020 Status changed from active, no longer recruiting to completed.
- 29 Jul 2020 Planned End Date changed from 1 Jun 2020 to 30 Sep 2020.